Industries > Pharma > Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027

Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027

Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies

PUBLISHED: 21 September 2017
PAGES: 207
PRODUCT CODE: PHA0241

Clear
WOOCS 2.2.1

The Alzheimer’s Disease Therapeutics and Diagnostics Market reached $6.71bn in 2016. The Alzheimer’s Disease Therapeutics and Diagnostics Market is expected to grow at a CAGR of 15.3% in the second half of the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 207-page report you will receive 73 tables and 76 figures– all unavailable elsewhere.

The 207-page report provides clear detailed insight into the Alzheimer’s Disease Therapeutics and Diagnostics Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Alzheimer’s Disease Market forecasts from 2017-2027, further broken down into:
– Alzheimer’s Drugs Market
– Alzheimer’s Diagnostics Market

• Quantitative analysis of the Alzheimer’s drug market from 2017 to 2027. It includes analysis and forecast of top drugs and pipeline drugs in the market:
– Namenda
– Aricept
– Exelon
– Solanezumab
– Gantenerumab
– Verubecestat

• Quantitative analysis of the Alzheimer’s diagnostics market from 2017 to 2027. In includes the guidelines and recent research and development in the field of diagnosis. There is further analysis and forecast provided for subsectors of Alzheimer’s diagnosis from 2017to 2027:
– Diagnostic biomarker market
– Others

• Profiles of leading pharma companies involved in developing Alzheimer’s drugs globally. It contains overviews of the companies’ segments, recent mergers and acquisitions and analysis of the companies’ recent financial performances. It also includes the details of the drugs for Alzheimer’s in the pipeline and forecast of the company drugs available in the market:
– Pfizer
– Eisai
– Actavis
– Lundbeck
– Daiichi Sankyo
– Novartis
– TauRx
– vTv Therapeutics

• Profiles of leading companies developing diagnostics tests for Alzheimer’s disease:
– Eli Lilly
– Amarantus Biosciences Holdings
– Piramal Enterprises
– GE Healthcare
– Navidea
– DiaGenic

Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027• This report also breaks down the revenue forecast for the Alzheimer’s Disease Market by national market:
– US
– Germany
– France
– Italy
– Spain
– UK
– Japan
– China
– Brazil
– India
– Russia

• This report covers the qualitative analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market. It includes SWOT analysis: Strengths, Weaknesses, Opportunities and Threats of the market.

• This report shows transcripts of research interviews conducted by Visiongain:
– David Hung, Chief Executive Officer of Axovant Sciences Inc.
– Dr. Gill Farrar, PET Neurology, Scientific Director at GE Healthcare
– Phyllis Ferrell, Vice President and Alzheimer’s Disease Global Platform Leader at Eli Lilly and Co.

Buy our report today Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027: Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027


Latest Pharma news

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

READ

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

READ

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

READ

Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022

READ

Categories